Furthermore, this study unravels one aspect of chondrosarcoma pathophysiology and provides insightful therapeutic possibilities such as combinatorial regimens of antiangiogenic agents with IDH1mut inhibitors for patients with advanced IDH mutated chondrosarcoma. Here, IDH1 is linked to chondrosarcoma.